SymBio Pharmaceuticals Limited (4582.T)
JPY 212.0
(-1.85%)
JPY 212.0
(-1.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.51 Billion JPY | -3.73% |
| 2022 | -6.28 Billion JPY | -62.76% |
| 2021 | -3.86 Billion JPY | -0.3% |
| 2020 | -3.84 Billion JPY | 1.59% |
| 2019 | -3.91 Billion JPY | 18.89% |
| 2018 | -4.82 Billion JPY | -63.6% |
| 2017 | -2.94 Billion JPY | 44.07% |
| 2016 | -5.26 Billion JPY | -23.67% |
| 2015 | -4.26 Billion JPY | 25.13% |
| 2014 | -5.69 Billion JPY | 7.64% |
| 2013 | -6.16 Billion JPY | -35.79% |
| 2012 | -4.53 Billion JPY | 0.39% |
| 2011 | -4.55 Billion JPY | -96.82% |
| 2010 | -2.31 Billion JPY | 40.69% |
| 2009 | -3.9 Billion JPY | -264.58% |
| 2008 | -1.07 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -5.12 Billion JPY | 19.34% |
| 2024 Q1 | -6.54 Billion JPY | -0.44% |
| 2024 Q2 | -6.35 Billion JPY | 2.86% |
| 2023 FY | -6.51 Billion JPY | -3.73% |
| 2023 Q2 | -6.07 Billion JPY | -2.3% |
| 2023 Q1 | -5.93 Billion JPY | 5.46% |
| 2023 Q3 | -6.11 Billion JPY | -0.64% |
| 2023 Q4 | -6.51 Billion JPY | -6.58% |
| 2022 Q2 | -5.8 Billion JPY | -38.8% |
| 2022 Q1 | -4.18 Billion JPY | -8.36% |
| 2022 FY | -6.28 Billion JPY | -62.76% |
| 2022 Q4 | -6.28 Billion JPY | -2.44% |
| 2022 Q3 | -6.13 Billion JPY | -5.64% |
| 2021 Q1 | -2.93 Billion JPY | 23.77% |
| 2021 FY | -3.86 Billion JPY | -0.3% |
| 2021 Q4 | -3.86 Billion JPY | -47.7% |
| 2021 Q3 | -2.61 Billion JPY | -12.32% |
| 2021 Q2 | -2.32 Billion JPY | 20.69% |
| 2020 Q3 | -4.72 Billion JPY | 12.61% |
| 2020 FY | -3.84 Billion JPY | 1.59% |
| 2020 Q4 | -3.84 Billion JPY | 18.59% |
| 2020 Q1 | -3.87 Billion JPY | 0.89% |
| 2020 Q2 | -5.4 Billion JPY | -39.56% |
| 2019 FY | -3.91 Billion JPY | 18.89% |
| 2019 Q3 | -4.62 Billion JPY | 23.75% |
| 2019 Q1 | -3.62 Billion JPY | 24.87% |
| 2019 Q2 | -6.06 Billion JPY | -67.48% |
| 2019 Q4 | -3.91 Billion JPY | 15.44% |
| 2018 Q4 | -4.82 Billion JPY | -25.49% |
| 2018 Q2 | -3.04 Billion JPY | 2.69% |
| 2018 Q1 | -3.13 Billion JPY | -6.35% |
| 2018 FY | -4.82 Billion JPY | -63.6% |
| 2018 Q3 | -3.84 Billion JPY | -25.99% |
| 2017 Q4 | -2.94 Billion JPY | 35.81% |
| 2017 FY | -2.94 Billion JPY | 44.07% |
| 2017 Q3 | -4.59 Billion JPY | 6.01% |
| 2017 Q2 | -4.88 Billion JPY | 3.16% |
| 2017 Q1 | -5.04 Billion JPY | 4.27% |
| 2016 FY | -5.26 Billion JPY | -23.67% |
| 2016 Q1 | -3.68 Billion JPY | 13.45% |
| 2016 Q4 | -5.26 Billion JPY | 2.48% |
| 2016 Q3 | -5.4 Billion JPY | -65.89% |
| 2016 Q2 | -3.25 Billion JPY | 11.68% |
| 2015 FY | -4.26 Billion JPY | 25.13% |
| 2015 Q3 | -5.16 Billion JPY | 7.64% |
| 2015 Q4 | -4.26 Billion JPY | 17.51% |
| 2015 Q2 | -5.59 Billion JPY | 6.49% |
| 2015 Q1 | -5.98 Billion JPY | -5.09% |
| 2014 Q3 | -4.85 Billion JPY | -1.19% |
| 2014 Q2 | -4.79 Billion JPY | 9.25% |
| 2014 FY | -5.69 Billion JPY | 7.64% |
| 2014 Q1 | -5.28 Billion JPY | 14.2% |
| 2014 Q4 | -5.69 Billion JPY | -17.24% |
| 2013 Q3 | -3.66 Billion JPY | -0.56% |
| 2013 Q4 | -6.16 Billion JPY | -68.01% |
| 2013 FY | -6.16 Billion JPY | -35.79% |
| 2013 Q1 | -4.94 Billion JPY | -9.03% |
| 2013 Q2 | -3.64 Billion JPY | 26.29% |
| 2012 FY | -4.53 Billion JPY | 0.39% |
| 2012 Q1 | -4.1 Billion JPY | 9.9% |
| 2012 Q2 | -3.3 Billion JPY | 19.56% |
| 2012 Q3 | -2.86 Billion JPY | 13.11% |
| 2012 Q4 | -4.53 Billion JPY | -58.15% |
| 2011 Q2 | -2.56 Billion JPY | -4.06% |
| 2011 Q3 | -2.32 Billion JPY | 9.53% |
| 2011 Q4 | -4.55 Billion JPY | -96.2% |
| 2011 FY | -4.55 Billion JPY | -96.82% |
| 2011 Q1 | -2.46 Billion JPY | -6.55% |
| 2010 FY | -2.31 Billion JPY | 40.69% |
| 2010 Q4 | -2.31 Billion JPY | 0.0% |
| 2010 Q2 | -2.06 Billion JPY | 0.0% |
| 2009 Q4 | -3.9 Billion JPY | 0.0% |
| 2009 Q2 | -1.14 Billion JPY | 0.0% |
| 2009 FY | -3.9 Billion JPY | -264.58% |
| 2008 Q4 | -1.07 Billion JPY | 0.0% |
| 2008 FY | -1.07 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 632.001% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.149% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 101.672% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 98.119% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | -82.85% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 84.541% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 89.399% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 93.345% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | -877.063% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 87.424% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 80.204% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 185.728% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 183.755% |
| Tsumura & Co. | 1.61 Billion JPY | 503.53% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 85.242% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 81.076% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 103.773% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 124.478% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 122.487% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 192.309% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 1025.711% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 208.762% |
| MedRx Co., Ltd | -1.72 Billion JPY | -278.896% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 25.233% |
| Solasia Pharma K.K. | -668 Million JPY | -875.6% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | -343.051% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 10.147% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 111.53% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | -120.112% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 93.379% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 41.444% |